Stock Events

Stock Events

Revolution Medicines 

$1.93
43
+$0.1+5.46% Thursday 19:58

Statistics

Day High
2
Day Low
1.81
52W High
2
52W Low
1.81
Volume
22,808
Avg. Volume
-
Mkt Cap
382.47M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.86
-1.54
-1.22
-0.89
Expected EPS
-1.819891
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-2.26BNet Income

Analyst Ratings

$124.14Average Price Target
The highest estimate is 170.00.
From 14 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RVMDW. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech giant that competes in the oncology space, developing treatments that could directly compete with Revolution Medicines' cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, including cancer, which puts it in direct competition with Revolution Medicines.
Merck
MRK
Mkt Cap214.76B
Merck is a global healthcare company that produces cancer drugs and therapies, competing with Revolution Medicines in the oncology market.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that develops and markets therapies in areas including oncology, competing with Revolution Medicines' cancer treatment portfolio.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical corporation with a broad range of oncology products, competing with Revolution Medicines in the cancer treatment space.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that has a strong focus on pharmaceuticals and biotechnology, including oncology, making it a competitor to Revolution Medicines.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie is a pharmaceutical company that engages in the discovery, development, manufacture, and sale of a broad line of healthcare products including oncology, competing with Revolution Medicines.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG is a healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its extensive work in oncology competes with Revolution Medicines.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, including for cancer, competing with Revolution Medicines.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions, including cancer, competing with Revolution Medicines.

About

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Show more...
CEO
Dr. Mark A. Goldsmith M.D., Ph.D.
Employees
616
Country
US
ISIN
US76155X1182

Listings

MI
IT
1RVMD.MI
BOATS
BOATS
RVMD.BOATS
XNAS
US
RVMD
XNAS
US
RVMDW

0 Comments

Share your thoughts

FAQ

What is Revolution Medicines stock price today?▼
The current price of RVMDW is $1.93 USD — it has increased by +5.46% in the past 24 hours. Watch Revolution Medicines stock price performance more closely on the chart.
What is Revolution Medicines stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Revolution Medicines stocks are traded under the ticker RVMDW.
Is Revolution Medicines stock price growing?▼
RVMDW stock has risen by +18.04% compared to the previous week, the month change is a +7.83% rise, over the last year Revolution Medicines has showed a +4,749.25% increase.
What is Revolution Medicines market cap?▼
Today Revolution Medicines has the market capitalization of 382.47M
When is the next Revolution Medicines earnings date?▼
Revolution Medicines is going to release the next earnings report on May 11, 2026.
What were Revolution Medicines earnings last quarter?▼
RVMDW earnings for the last quarter are -1.86 USD per share, whereas the estimation was -1.58 USD resulting in a -17.63% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Revolution Medicines revenue for the last year?▼
Revolution Medicines revenue for the last year amounts to 0 USD.
What is Revolution Medicines net income for the last year?▼
RVMDW net income for the last year is -2.26B USD.
How many employees does Revolution Medicines have?▼
As of April 05, 2026, the company has 616 employees.
In which sector is Revolution Medicines located?▼
Revolution Medicines operates in the Health Care sector.
When did Revolution Medicines complete a stock split?▼
Revolution Medicines has not had any recent stock splits.
Where is Revolution Medicines headquartered?▼
Revolution Medicines is headquartered in Redwood City, US.